Anthropic’s reported path toward the public markets is drawing attention to a governance structure that is unusual even by artificial intelligence standards. Ars Technica reports that the Claude maker is planning an initial public offering that could value the company at as much as $2 trillion, forcing prospective investors to evaluate not just growth and model performance, but who ultimately controls the board. At the center is Anthropic’s Long-Term Benefit Trust, or LTBT. According to Ars, the trust was created to protect the company’s mission of developing AI for the long-term benefit of humanity as commercial pressure rises. The structure is notable because the trust holds no equity in Anthropic, yet has substantial formal power over the company’s governance. Ars reports that the LTBT is the controlling governance mechanism for Anthropic’s public benefit corporation and has the right to appoint or dismiss a majority of the board. It has selected four of Anthropic’s seven directors, including Netflix co-founder Reed Hastings and Vas Narasimhan, the chief executive of Novartis. That means a non-equity body has influence over the board composition investors would face after any public listing. The trust itself remains small. Ars says it currently has three members out of a possible five: Neil Buddy Shah, chief executive of the Clinton Health Access Initiative, who chairs the trust; former Federal Reserve chair Ben Bernanke; and Richard Fontaine, chief executive of the Center for a New American Security. Mariano-Florentino “Tino” Cuéllar, a former California Supreme Court justice, left the trust after a few months to become Anthropic’s chief global affairs officer. People close to Anthropic’s plans told Ars the company is trying to make the LTBT a template for future AI governance. Those people compared the ambition to generally accepted accounting principles, which began as voluntary private-sector standards before becoming institutionalized. Ars reports that one person described Bernanke’s July appointment as a signal that Anthropic wants to make the trust more institutional. The trust also appears to have close operational visibility. According to Ars, trustees are required to receive advance notice of major company actions, including launches of new AI models. The report says they meet weekly among themselves, meet Anthropic leadership as often as every other week, attend regular board meetings and speak with founders about significant issues. Ars reports that those discussions have included Anthropic’s Mythos cybersecurity model, where trustees encouraged a limited rollout through the Glasswing Project, as well as the company’s dispute with the US government over automated weapons. But the same report says the trust has largely acted in an advisory role so far. A person familiar with its workings told Ars it has not drawn firm red lines or forced a significant trade-off between profit and purpose. That unresolved test is the key governance question for public-market investors. Ars cites Jesse Fried, a Harvard Law School professor and corporate governance expert, describing the structure as a built-in conflict. The issue is not whether the trust has formal authority; Ars reports that it does. The issue is how that authority would be used if Anthropic’s commercial goals and stated societal mission diverge after a public listing. Who benefits: Anthropic benefits if the structure helps it credibly signal long-term AI-safety commitments to employees, policymakers and mission-aligned investors. The trustees also gain an unusually visible role in the governance of a major AI company. Who's exposed: Prospective shareholders are exposed to uncertainty over how the trust would act in a real conflict between commercial returns and Anthropic’s stated mission. Anthropic’s leadership is also exposed to greater scrutiny if the trust’s formal powers remain mostly advisory in practice.